Q32 Bio Inc.
NASDAQ:QTTBBiotechnology
-$0.22 today
- Market cap
- $258.24M
- Beta
- -0.23
- P/E (TTM)
- 5.4
- EPS (TTM)
- $2.36
Volume 0.62M
Average 0.74M
QTTB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Q32 Bio Inc.NASDAQ: QTTB
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$7.63M, compared with -$10.61M a year earlier. Trailing-twelve-month EBITDA was $22.15M.
Context
- EBITDA amounted to 32.2% of revenue in FY2025.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$15.64M (-190.4%) for the fiscal year ending Dec 2026, a slowdown from the +138.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.63M-116.6% QoQ
- Last fiscal yearDec 2025
- $17.29M+138.2% YoY
- LTMMar 2026
- $22.15M+154.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +28.1% | -92.9% | -121.0 pp |
| 1 year | +138.2% | -190.4% | -328.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | -17.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 17.29M USD
- Year-over-year change
- +138.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.29M | +138.2% |
| FY2024 | 2024-12-31 | (45.3M) | +5.1% |
| FY2023 | 2023-12-31 | (47.76M) | -22.9% |
| FY2022 | 2022-12-31 | (38.86M) | +54.9% |
| FY2021 | 2021-12-31 | (86.22M) | — |
EBITDA vs competitors
How QTTB compares with its peers on the latest reported figures
- QTTB's LTM Mar 2026 EBITDA of $22.15M is the highest of the 5 companies compared; the peer median is -$23.6M.
- Its year-over-year change of +154.8% is the highest of 5, against a peer median of +43.4%.
- EBITDA amounts to 41.2% of revenue for QTTB, versus a peer median of 30.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.15M | +154.8% | — | 41.2% | |
| LTM Jun 2026 | -$9.46M | +71.7% | — | — | |
| LTM Mar 2026 | -$11.36M | +79.6% | — | 30.6% | |
| LTM Mar 2026 | -$35.85M | -213.1% | — | — | |
| LTM Mar 2026 | -$54.78M | +15.1% | — | — | |
| Peer median (excluding QTTB) | -$23.6M | +43.4% | — | 30.6% | |
Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.97M | 6.65M | (6.65M) | 0 | 53.74M |
| Cost of Revenue | 9.54M | 2.6M | 499K | 487K | 391K |
| Gross Profit | 24.43M | 6.65M | (6.65M) | (487K) | 53.35M |
| Gross Margin | 71.9% | 100.0% | 100.0% | — | 99.3% |
| Research & Development | 93.09M | 35.81M | 31.73M | 48.14M | 19.16M |
| Selling, General & Admin | 27.29M | 10.06M | 9.88M | 17.47M | 17.68M |
| Operating Expenses | 120.38M | 45.88M | 41.6M | 65.61M | 36.44M |
| Depreciation & Amortization | 9.54M | 370K | 499K | 487K | 391K |
| EBITDA | (86.22M) | (38.86M) | (47.76M) | (45.3M) | 17.29M |
| EBITDA Margin | -253.8% | -584.2% | 718.0% | — | 32.2% |
| Operating Income | (95.95M) | (39.23M) | (48.26M) | (66.1M) | 16.9M |
| Operating Margin | -282.4% | -589.8% | 725.5% | — | 31.5% |
| Interest Income | 185K | 3.23M | 0 | 3.9M | 2.2M |
| Interest Expense | 0 | 0 | 0 | 300K | 1.1M |
| Other Income / Expenses | 185K | (3.52M) | (5.17M) | 18.39M | 12.92M |
| Income Before Tax | (95.76M) | (42.75M) | (53.43M) | (47.71M) | 29.82M |
| Pre-Tax Margin | -281.9% | -642.7% | 803.3% | — | 55.5% |
| Income Tax Expense | 0 | 62K | 318K | 21K | 0 |
| Net Income | (95.76M) | (42.81M) | (53.74M) | (47.73M) | 29.82M |
| Net Margin | -281.9% | -643.6% | 808.0% | — | 55.5% |
| EPS (Basic) | (31.18) | (13.42) | (16.70) | (5.12) | 2.42 |
| EPS (Diluted) | (31.18) | (13.42) | (16.70) | (6.58) | 2.42 |
| Weighted Avg Shares | 3.07M | 3.19M | 3.22M | 12.2M | 12.3M |
| Weighted Avg Shares (Diluted) | 3.07M | 3.19M | 3.22M | 12.2M | 12.31M |
Q32 Bio Inc.
NASDAQ:QTTB
Intrinsic Alpha fair value
Locked
Current Price
$8.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.